ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Feng J, Lu PZ, Zhu GZ, Hooi SC, Wu Y, Huang XW, Dai HQ, Chen PH, Li ZJ, Su WJ, Han CY, Ye XP, Peng T, Zhou J, Lu GD.
Feng J, et al. Among authors: wu y.
Acta Pharmacol Sin. 2021 Jan;42(1):160-170. doi: 10.1038/s41401-020-0439-x. Epub 2020 Jun 15.
Acta Pharmacol Sin. 2021.
PMID: 32541921
Free PMC article.